Persistent STAT3 signaling has been observed in numerous malignancies, and growing preclinical evidence underscores the effectiveness of targeting STAT3 in the treatment of various cancers, including bladder cancer [21,22,23]. Here, STAT3 is linked to urinary bladder carcinoma.